Published in final edited form as:

J Nat Prod. 2011 May 27; 74(5): 1169–1174. doi:10.1021/np200093n.

Isolation and Synthesis of Antiproliferative Eupolauridine Alkaloids of *Ambavia gerrardii* from the Madagascar Dry Forest¹

Ende Pan[†], Shugeng Cao^{†,‡}, Peggy J. Brodie[†], Martin Callmander[§], Richard Randrianaivo[§], Stephan Rakotonandrasana[‡], Etienne Rakotobe[‡], Vincent E. Rasamison[‡], Karen TenDyke^{||}, Yongchun Shen^{||}, Edward M. Suh^{||}, and David G. I. Kingston^{*,†}

[†]Department of Chemistry, M/C 0212, Virginia Polytechnic Institute and State University, Blacksburg, VA 24061-0212

[§]Missouri Botanical Garden, B.P 3391, Antananarivo 101, Madagascar

[‡]Centre National d'Application des Recherches Pharmaceutiques, B.P 702, Antananarivo 101, Madagascar

^{||}Next Generation Systems, Eisai Inc., 4 Corporate Drive, Andover, Massachusetts 01810

Abstract

Investigation of the Madagascan endemic plant *Ambavia gerrardii* (Baill.) Le Thomas (Annonaceae) for antiproliferative activity against the A2780 ovarian cancer cell line led to the isolation of the three new alkaloids 8-hydroxyeupolauridine (**1**), 9-methoxyeupolauridine 1-oxide (**2**) and 11-methoxysampangine (**3**), and the three known alkaloids **4–6**. The structures of **1** and **2** were confirmed by synthesis. Compounds **3**, **4**, and **6** showed moderate to good antiproliferative activities, with IC₅₀ values of 10.3, 3.5, and 0.60 μM, respectively, against the A2780 human ovarian cancer cell line, and with IC₅₀ values of 0.57, 1.77, and 0.58 μM, respectively, against the H460 human lung cancer cell line.

In our continuing search for biologically active natural products from tropical forests as part of an International Cooperative Biodiversity Group (ICBG) program, we obtained an EtOH extract from the roots of a plant identified as *Ambavia gerrardii* (Baill.) Le Thomas (Annonaceae) from Madagascar. The extract exhibited good antiproliferative activity against the A2780 human ovarian cancer cell line with an IC₅₀ value of 10 μg/mL. The genus *Ambavia* (Annonaceae) consists of only two species, *A. capuronii* and *A. gerrardii*, both of which are endemic to Madagascar, and no phytochemical work has been reported on either species. Previous phytochemical studies of plant species in the Annonaceae family have revealed the presence of cytotoxic acetogenins,^{2, 3} miliusanes,⁴ styrylpyrones,⁵ polyacetylenes,⁶ diterpenoids,^{7, 8} flavanones,⁹ and alkaloids.^{6,10} The extract was selected for bioassay-directed fractionation to isolate its active components on the basis of its activity and the absence of previous phytochemical studies.

*To whom correspondence should be addressed. Tel: (540) 231-6570. Fax: (540) 231-3255. dkingston@vt.edu.

[‡]Current address: Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Harvard University, 240 Longwood Avenue, Boston MA 02115.

Supporting Information Available: ¹H and ¹³C NMR spectra of **1–2** and **7–11** and ¹H NMR spectra of **3–6**. These materials are available free of charge via the Internet at <http://pubs.acs.org>.

Results and Discussion

An EtOH extract of the roots of *A. gerrardii* was subjected to liquid-liquid partitioning between hexanes, CH₂Cl₂ and MeOH to give fractions with IC₅₀ values of 14 µg/mL, 2.6 µg/mL and >100 µg/mL, respectively, in the A2780 assay. Fractionation of the active CH₂Cl₂ fraction by C18 open column and high performance liquid chromatography (HPLC) yielded two new eupolauridine derivatives (**1** and **2**), the new 11-methoxysampangine (**3**), as well as eupolauridine N-oxide (**4**), eupolauridine (**5**) and sampangine (**6**). The structures of compounds **1** and **2** were proposed on the basis of their UV, IR, HRESIMS and ¹H NMR spectra data, but the limited samples available combined with the absence of ¹³C NMR data and HMBC correlations made it necessary to confirm the structures by synthesis. The synthesis also provided material for the evaluation of the biological activities of **1** and **2**. Herein we report the isolation and structure elucidation of compounds **1–3**, the synthesis of compounds **1–2**, and the antiproliferative activities of all isolates.

Eupolauridine N-oxide (**4**),¹¹ eupolauridine (**5**)¹¹ and sampangine (**6**)^{12–14} were all obtained as yellow solids. Eupolauridine (**5**) was previously isolated from the annonaceous plant *Cananga odorata* (Ylang ylang) collected in Madagascar,¹⁵ and from the eupomatiaceous plant *Eupomatia laurina*.¹⁶

Compound **1** was obtained as a yellow solid. Its UV absorptions in MeOH, with λ_{max} (log ε) 220 (4.15), 240 (3.98), 287 (3.82), 351 (3.28), and 369 (3.35) nm, indicated the presence of an extended aromatic chromophore similar to that of eupolauridine **5**. The IR spectroscopic data of compound **1**, which showed absorptions at 1599, 1580, 1398, 1378, 1202, 848 and 808 cm⁻¹, confirmed the existence of the aromatic and C-O functions. The positive ion HRESIMS of **1** revealed a pseudomolecular ion peak at *m/z* 21.0702 [M + H]⁺ corresponding to a molecular formula of C₁₄H₁₀N₂O, (calcd for C₁₄H₉N₂O: 221.0715). Its ¹H NMR signals in CD₃OD exhibited AB, A'B' and A"B'X" multiplets at low field: [δ_H 8.64 (1H, d, *J* = 6.1 Hz), 8.55 (1H, d, *J* = 6.1 Hz), 7.78 (1H, d, *J* = 8.2 Hz), 7.61 (1H, d, *J* = 6.1 Hz), 7.51 (1H, d, *J* = 6.1 Hz), 7.42 (1H, d, *J* = 2.3 Hz), 6.86 (1H, dd, *J* = 8.2, 2.3 Hz)]. The above data together with the fact that **1** and **5** (C₁₄H₁₀N₂) have the same unsaturation number (12) suggested that compound **1** was a hydroxylated eupolauridine. The position of the OH group was assigned at C-8 from the coupling patterns of the protons of the benzene ring of **1** [δ_H 7.78 (1H, d, *J* = 8.2 Hz), 6.86 (1H, dd, *J* = 8.2, 2.3 Hz) and 7.42 (1H, d, *J* = 2.3 Hz)] and comparison of the ¹H NMR spectroscopic data of **1** with those of **5** [δ_H 8.71 (2H, d, *J* = 6.0 Hz), 8.01 (2H, m), 7.67 (2H, d, *J* = 6.0 Hz), 7.55 (2H, m)]. Based on the above data, we proposed the structure of 8-hydroxyeupolauridine for compound **1**.

Compound **2** was also obtained as a yellow solid. It showed strong UV absorptions (MeOH) at λ_{max} (log ε) 225 (4.03), 254 (3.99), 292 (3.87), and 384 (3.36) nm. Its IR spectrum displayed aromatic absorptions at 1611, 1593, 1569, 1451, 1423, 846, 828 cm⁻¹, a C-O stretch absorption at 1022 cm⁻¹, and N-O stretch absorptions at 1487 and 1380 cm⁻¹. The characteristic alkyl C-H stretch absorptions were also observed at 2919 and 2851 cm⁻¹. The

positive ion HRESIMS of **2** displayed a pseudomolecular ion peak at m/z 251.0811 [$M + H$]⁺, corresponding to a molecular formula of C₁₅H₁₁N₂O₂, (calcd for C₁₅H₁₁N₂O₂: 251.0821). Its proton spectrum [AB, A'B' and A''B''X" aromatic coupling pattern and one OCH₃ group: δ_H 8.58 (1H, d, $J = 6.0$ Hz), 8.23 (1H, d, $J = 7.1$ Hz), 7.95 (1H, d, $J = 8.2$ Hz), 7.92 (1H, d, $J = 2.4$ Hz), 7.79 (1H, d, $J = 7.1$ Hz), 7.57 (1H, d, $J = 6.0$ Hz), 7.09 (1H, dd, $J = 8.2, 2.4$ Hz)] was very similar to that of **1** except for the presence of a signal for an additional methyl group at δ_H 3.96 (3H, s). The above spectroscopic data thus suggested that **2** was either 8-methoxyeupolauridine N¹-oxide or 9-methoxyeupolauridine N¹-oxide, but the available data did not permit a distinction between these two structures. It was thus necessary to synthesize **1** and **2** to confirm the structure of **1** and to provide additional material for bioassay, and to determine the position of the N-oxide in **2**.

The synthesis of 8-hydroxyeupolauridine (**1**) initially followed Wong's method for synthesizing eupolauridine,¹⁷ using 5-methoxy-1,3-indanedione as the starting material instead of the 1,3-indanedione of the published method. The key step to afford 7-methoxyonychin (**9**) involved the thermal rearrangement of an oxime *O*-crotyl ether, and this gave a very low yield of product (<10%) in our hands. We thus changed the synthetic strategy by modifying Bracher's synthesis of eupolauridine (**5**) (Scheme 1).¹⁸ Ethyl 3-(4-methoxyphenyl)-3-oxopropionate was deprotonated by NaH, then underwent Michael addition with crotonaldehyde to afford the intermediate α -(1-methyl-3-oxopropyl)- β -oxo-4-methoxyl-benzenepropanoic acetate, which reacted with hydroxylamine hydrochloride to give ethyl 2-(4-methoxy)phenyl-4-methyl-3-pyridinecarboxylate (**7**). Although polyphosphoric acid was reported to catalyze the formation of onychin from ethyl 2-phenyl-4-methyl-3-pyridinecarboxylate in good yield,¹⁸ a very low yield of product was obtained when **7** was used as a substrate in the study. Compound **7** was thus hydrolyzed to the corresponding nicotinic acid **8**, which was then converted to its acyl chloride by treatment with thionyl chloride. A Friedel-Crafts reaction of the acyl chloride in chlorobenzene under reflux gave 7-methoxy onychin (**9**). The acidic methylene group of **9** reacted with dimethylformamide diethyl acetal to afford an enamine intermediate, which yielded 8-methoxy eupolauridine (**10**) through a ring closing reaction of the intermediate in the presence of ammonium acetate at 140 °C. Cleavage of the methyl ether of **10** in 48% HBr gave 8-hydroxyeupolauridine (**1**) in 1.7 % overall yield from **7**. Comparison of the ¹H NMR (Table 1) and HRESIMS data of 8-hydroxyeupolauridine with the data of compound **1** confirmed the proposed structure of the isolated natural product.

Mono-oxidation of 8-methoxyeupolauridine (**10**) by one equivalent of *meta*-chloroperoxybenzoic acid yielded the two methoxyeupolauridine N-oxides in a 3.7:1 ratio in 2.7 % overall yield; the ¹H NMR data for the major product matched the corresponding data of the natural product **2**, and differed from that of the isomeric product **11**. Comparison of the ¹H NMR data of **2** and **11** (Table 1) indicated that the proton signals of H-10 for **2** [δ_H 7.95 (d, $J = 8.2$ Hz)] were less deshielded than those of **11** [δ_H 8.21 (d, $J = 8.4$ Hz)]. On the other hand the signals for H-7 of **2** [δ_H 7.92 (d, $J = 2.4$ Hz)] were more deshielded than those of **11** [δ_H 7.61 (d, $J = 2.3$ Hz)]. These differences enabled the structures of **2** and **11** to be assigned. The larger deshielding of H-10 of **11** and of H-7 of **2** were consistent with the major resonance structures of each compound. For compound **2** the favored resonance structure is expected to be the one that puts the negative charge on the positively charged oxygenated nitrogen (structure **2a**) rather than a structure such as **2b** where the charge ends up on the neutral nitrogen atom; this means that H-7 will be preferentially deshielded. The situation is reversed for structure **11**, where the most stable resonance structure **11a** results in deshielding of H-10, and the less favored resonance structure **11b** is the one that deshields H-7 (Figure 1). HMBC correlations of **2** from both downfield shifted H-5 (δ_H 8.23) and H-7 (δ_H 7.92) to C-6a (δ_C 144.0) confirmed it to be 9-methoxyeupolauridine-1-oxide.

11-Methoxysampangine (**3**) was obtained as a yellow solid and had a molecular mass of 263.1, consistent with the composition $C_{16}H_{11}N_2O_2$. Its 1H NMR signals in $CDCl_3$ exhibited AB, A'B' and A''B''C'' multiplets at low field: δ_H 8.88 (1H, d, $J = 5.8$ Hz), 7.71 (1H, d, $J = 5.8$ Hz), 7.86 (1H, d, $J = 5.8$ Hz), 9.11 (1H, d, $J = 5.8$ Hz), 7.26 (1H, d, $J = 8.0$ Hz), 7.77 (1H, t, $J = 8.0$ Hz), and 8.56 (1H, d, $J = 8.0$ Hz). A triplet at δ_H 7.77 with a coupling constant of 8.0 Hz indicated the presence of a contiguous group of three aromatic protons, and limited the possible structures to either 8-methoxysampangine (**12**) or 11-methoxysampangine (**3**). The 8-methoxysampangine structure **12** was initially favored, based on the absence of a 3J HMBC correlation from the H-8 aromatic proton to the C-7 carbonyl carbon, but a comparison of its 1H NMR spectrum with that of synthetic 8-methoxysampangine prepared by Zjawiony et al.¹⁹ indicated that the two compounds were not identical. Although a sample for direct comparison was not available, Dr. Zjawiony confirmed the structure of his synthetic compound by a comparison of the NMR data of his intermediates with data in the supporting information of a recent paper.^{20, 21} These facts exclude the 8-methoxysampangine structure, and so the structure of compound **3** is assigned as 11-methoxysampangine. The lack of sample regrettably precluded additional experiments to confirm this assignment.

The biosyntheses of these two types of alkaloids have been proposed by Taylor.²² It was reported that sampangine (**6**) could derive from a dihydroxyoxoaporphine. Then eupolauridine (**5**) could arise from sampangine (**6**) through a ring-contraction pathway with concurrent loss of carbon monoxide.

Previous research has shown eupolauridine to have antifungal activity,²³ and sampangine derivatives to have cytotoxic, antimalarial, and antifungal activities.²⁴ 8-Hydroxyeupolauridine (**1**), 9-methoxyeupolauridine 1-oxide (**2**), 8-methoxyeupolauridine (**10**), and 8-methoxyeupolauridine 1-oxide (**11**), as well as 11-methoxysampangine (**3**), eupolauridine N-oxide (**4**), eupolauridine (**5**), and sampangine (**6**) were tested against the A2780 human ovarian cancer cell line. Among these eight compounds, sampangine (**6**) was the most active against the A2780 cell line with an IC_{50} value of 0.60 μM , but sampangine derivative **3** showed much weaker activity, with IC_{50} 10.3 μM . Among the eupolauridine analogues, compound **4** was the most active with an IC_{50} value of 3.5 μM .

When tested against the H460 human non-small cell lung cancer cell line, compounds **3** and **6** both exhibited strong activity with IC_{50} values of 0.57 μM and 0.58 μM , respectively. Interestingly, only **4** among the eupolauridine analogues showed antiproliferative activity against this cell line, with an IC_{50} value of 1.77 μM .

Experimental Section

General Experimental Procedures

UV was measured on a Shimadzu UV-1201 spectrophotometer. IR spectra of solid samples were obtained directly on a MIDAC M-series FTIR spectrophotometer. Melting points were obtained on a B-540 Büchi melting-point apparatus. NMR spectra were recorded in $CDCl_3$, CD_3OD or D_2O on either JEOL Eclipse 500 or Bruker 600 spectrometers. The chemical shifts are given in δ (ppm) and coupling constants (J) are reported in Hz. Mass spectra were obtained on an Agilent 6220 TOF Mass Spectrometer. HPLC was performed on a Shimadzu LC-10AT instrument with a semi-preparative C18 or phenyl Varian Dynamax column (5 μm , 250 $\times$ 10 mm). Unless otherwise noted, chemicals were obtained from commercial suppliers and used without purification. Solvents were dried if necessary by standard methods. All reactions were performed under air atmosphere unless otherwise noted.

Plant Material

Roots of *Ambavia gerrardii* were collected on July 15, 2005, in the Ambohibe dry forest near the village of Betsimiranja, Diana, Antsiranana, Madagascar. The collection coordinates were 13° 02' 42" S, 049° 09' 11" E, and the elevation was 50 m. The plant sampled was a tree of about 16 m height with a diameter at breast height of 35 cm, and with green fruit; it occurs commonly in this area. The tree was identified by R. Randrianaivo, and its identity was confirmed by G.E. Schatz (Missouri Botanical Garden). Voucher specimens with collection number Randrianaivo & al. 1196 have been deposited in herbaria at the Parc Botanique and Zoologique de Tsimbazaza (TAN), at the Centre National d'Application des Recherches Pharmaceutiques in Antananarivo, Madagascar (CNARP), at the Missouri Botanical Garden in St. Louis, Missouri (MO), and at the Muséum National d'Histoire Naturelle in Paris, France (P).

Extraction and Isolation

Dried roots of *Ambavia gerrardii* (250 g) were ground in a hammer mill, then extracted with EtOH by percolation for 24 hours at room temperature to give the crude extract MG 3311 (6.4 g), of which 3.0 g was available at Virginia Polytechnic Institute and State University (VPIU) for evaluation. The extract MG 3311 (IC₅₀ 3.6 µg/mL, 1.3 g) was suspended in aqueous MeOH (MeOH-H₂O, 9:1, 100 mL) and extracted with hexanes (3 × 100 mL portions). The aqueous layer was then diluted to 60% MeOH (v/v) with H₂O and extracted with CH₂Cl₂ (3 × 150 mL portions). The hexanes extract was evaporated in vacuo to leave 138 mg with an IC₅₀ value of 14 µg/mL. The residue from the CH₂Cl₂ extract (354 mg) had an IC₅₀ value of 2.6 µg/mL. The aqueous MeOH extract (715 mg) was inactive. The CH₂Cl₂ extract was selected for fractionation, and six fractions of 124, 44, 81, 26, and 38 mg were collected from a C18 open column eluted with MeOH/H₂O (gradient from 60% to 100%). The first four fractions had IC₅₀ values of 3.7, 1.9, 3, and 16 µg/mL, respectively, and the last fraction was inactive. Fractions I and II were selected for further work. Separation of fraction I by C-18 preparative HPLC (60% MeOH-H₂O) yielded eight subfractions (IC₅₀ 19 µg/mL, inactive, inactive, 3.2 µg/mL, inactive, 2 µg/mL, 4.9 µg/mL and inactive), and the most active subfractions I-4 (IC₅₀ 3.2 µg/mL), and I-6 (IC₅₀ 2 µg/mL) were selected for further separation by phenyl HPLC (60% MeOH-H₂O). Compounds **1** (0.4 mg, t_R 28.1 min) and **4** (2.0 mg t_R 31.4 min) were isolated from subfraction I-4, and compounds **2** (0.5 mg, t_R 29.8 min), and **3** (1.0 mg, t_R 36.0 min) were isolated from subfraction I-6. Fraction II was applied to a C18 open column. The most active subfraction (IC₅₀ 0.14 µg/mL) was subjected to phenyl HPLC (70% MeOH-H₂O) to give compounds **5** (1.9 mg, t_R 25.3 min) and **6** (0.6 mg, t_R 31.4 min).

8-Hydroxyeupolauridine (1)

yellow solid. UV (MeOH) λ_{max} nm (log ε) 220 (4.15), 240 (3.98), 287 (3.82), 351 (3.28), 369 (3.35); IR ν_{max} cm⁻¹: 1638, 1599, 1580, 1398, 1378, 1289, 1243, 1202, 1091, 1060, 1016, 994, 842 and 808 cm⁻¹. ¹H NMR (500 MHz, CD₃OD), see Table 1; HRESI-MS m/z 221.0713 [M + H]⁺ (calcd for C₁₄H₁₀N₂O, 221.0715).

9-Methoxyeupolauridine 1-oxide (2)

yellow solid; UV (MeOH) λ_{max} nm (log ε) 225 (4.03), 254 (3.99), 292 (3.87), 384 (3.36); IR ν_{max} cm⁻¹: 2919, 2851, 1611, 1593, 1487, 1451, 1423, 1380, 1256, 1233, 1022, 973, 846 and 828 cm⁻¹. ¹H NMR (500 MHz, CD₃OD) and ¹³C NMR (125 MHz, CD₃OD), see Table 1; HRESI-MS m/z 251.0820 [M + H]⁺ (calcd for C₁₅H₁₁N₂O₂, 251.0821).

11-Methoxysampangine (3)

yellow solid; LC-MS m/z 263.1 $[M + H]^+$ (calcd for $C_{16}H_{11}N_2O_2$, 263.1). 1H NMR (500 MHz, $CDCl_3$), see Table 1.

Eupolauridine N-oxide (4)

yellow solid; LC-MS m/z 221.1 $[M + H]^+$ (calcd for $C_{14}H_9N_2O$, 221.1). 1H NMR (500 MHz, $CDCl_3$), see supporting information.

Eupolauridine (5)

yellow solid; LC-MS m/z 205.1 $[M + H]^+$ (calcd for $C_{14}H_9N_2$, 205.1). 1H NMR (500 MHz, $CDCl_3$), see supporting information.

Sampangine (6)

yellow solid; LC-MS m/z 233.0 $[M + H]^+$ (calcd for $C_{15}H_9N_2O$, 233.1). 1H NMR (500 MHz, $CDCl_3$), see supporting information.

Ethyl 2-(4-methoxy)phenyl-4-methyl-3-pyridinecarboxylate (7)

To a solution of 3.84 g (17 mmol) ethyl 3-(4-methoxyphenyl)-3-oxopropionate in 14 mL dioxane in a 100 mL flask was added 48 mg (2 mmol) NaH, and then 1.68 g (24 mmol) crotonaldehyde dropwise in 6 mL dioxane. After the reaction mixture was stirred for another 30 min at room temperature, 4.9 g of $H_2NOH \cdot HCl$ (70 mmol) and 20 mL glacial AcOH were added. The reaction mixture was stirred at 100–110 °C for 90 minutes and then poured onto 100 g of ice, made basic with K_2CO_3 and extracted with ether (3×100 mL). The combined organic phase was extracted with 2N HCl (3×100 mL). The combined acidic aqueous phase was neutralized with K_2CO_3 and extracted with ether (3×100 mL), and the ether was dried over K_2CO_3 and evaporated under reduced pressure. The oily crude product was purified by flash silica column chromatography (hexane:EtOAc, 4:1) to afford ethyl 2-(4-methoxy)phenyl-4-methyl-3-pyridinecarboxylate (**7**) (1.47 g, 32%): yellow oil. 1H NMR (500 MHz, $CDCl_3$) δ_H 8.53 (1H, d, $J = 5.1$ Hz), 7.54 (2H, d, $J = 8.8$ Hz), 7.08 (1H, d, $J = 5.1$ Hz), 6.94 (2H, d, $J = 8.8$ Hz), 4.17 (2H, q, $J = 7.2$ Hz), 3.82 (3H, s), 2.39 (3H, s), 1.08 (3H, t, $J = 7.2$ Hz); ^{13}C NMR (125 MHz, $CDCl_3$) δ_C 168.8, 160.0, 156.0, 149.4, 145.4, 132.4, 129.6, 128.9, 123.1, 113.7, 61.3, 55.2, 19.3, 13.7; HRESI-MS m/z 272.1268 $[M + H]^+$ (calcd for $C_{16}H_{18}NO_3$, 272.1287).

2-(4-Methoxyphenyl)-4-methyl-3-pyridinecarboxylic acid (8)

Compound **7** (670 mg, 2.5 mmol) was refluxed overnight in aqueous NaOH (40%, 10 mL). The solution was extracted with $CHCl_3$ to remove any unreacted starting material. The pH value of the mixture was then adjusted to about 6, the solvent was removed under reduced pressure, and the residue was extracted with hot MeOH (3×10 mL). The MeOH extracts were combined and concentrated to a residue which was purified on a silica column eluted with MeOH: CH_2Cl_2 (3:1) to give 2-(4-methoxyphenyl)-4-methyl-3-pyridinecarboxylic acid (**8**) (403 mg, 66%): off-white solid, mp 198–200 °C; 1H NMR (500 MHz, D_2O) δ_H 8.43 (1H, d, $J = 6.2$ Hz), 7.78 (1H, d, $J = 6.2$ Hz), 7.62 (2H, d, $J = 9.0$ Hz), 7.13 (2H, d, $J = 9.0$ Hz), 3.89 (3H, s), 2.59 (3H, s); ^{13}C NMR (125 MHz, D_2O) δ_C 171.6, 161.8, 155.4, 147.6, 139.1, 130.3, 126.7, 123.6, 115.0, 55.7, 49.0, 20.2; HRESI-MS m/z 244.0958 $[M + H]^+$ (calcd for $C_{14}H_{14}NO_3$, 244.0974).

7-Methoxyonychin (9)

A solution of **8** (93 mg, 0.38 mmol) in 2 mL $SOCl_2$ was refluxed 24 h under N_2 . After the solvent was removed under vacuum, 51 mg (0.38 mmol) $AlCl_3$ and 2 mL chlorobenzene

were added to the flask and the mixture was refluxed overnight under N₂. The reaction was cooled and quenched by pouring into 10 mL of saturated NaHCO₃ solution. The resulting mixture was extracted with CH₂Cl₂ (3 × 10 mL), dried over K₂CO₃, and the CH₂Cl₂ phase was evaporated. The residue was purified by silica gel PTLC (hexanes:EtOAc, 6:4) to afford 7-methoxyonychin (**9**) (21 mg, 25%): yellow solid, mp 134–136 °C; ¹H NMR (500 MHz, CDCl₃) δ_H 8.30 (1H, d, *J* = 5.2 Hz), 7.79 (1H, d, *J* = 8.2 Hz), 7.18 (1H, d, *J* = 2.3 Hz), 7.04 (1H, dd, *J* = 8.2, 2.3 Hz), 6.90 (1H, d, *J* = 5.2 Hz), 3.87 (3H, s), 2.59 (3H, s); ¹³C NMR (125 MHz, CDCl₃) δ_C 192.4, 164.8, 162.5, 151.3, 148.2, 136.9, 134.5, 126.1, 125.0, 122.7, 120.4, 109.0, 55.8, 17.3; HRESI-MS *m/z* 226.0865 [M + H]⁺ (calcd for C₁₄H₁₂NO₂, 226.0868).

8-Methoxyeupolauridine (10)

A solution of 33 mg (0.15 mmol) of **9**, plus *N,N*-dimethylformamide diethyl acetal in 1 mL DMF was stirred 2 h at 120 °C under N₂. NH₄OAc (600 mg) was added to the flask and the reaction mixture was stirred for another 30 min at 140 °C, quenched with 5 mL water, and the solvent was extracted with EtOAc (3 × 5 mL). The organic phase was combined, dried over K₂CO₃ and concentrated to a residue which was separated on a silica TLC plate (hexanes:EtOAc, 6:4) to give 8-methoxy eupolauridine (**10**) (25.4 mg, 74%): yellow solid, mp 138–140 °C; ¹H NMR (500 MHz, CDCl₃) δ_H 8.63 (1H, d, *J* = 5.7 Hz), 8.57 (1H, d, *J* = 5.7 Hz), 7.81 (1H, d, *J* = 8.2 Hz), 7.49 (1H, d, *J* = 1.4 Hz), 7.35 (1H, d, *J* = 5.7 Hz), 7.28 (1H, d, *J* = 5.7 Hz), 6.89 (1H, dd, *J* = 8.2, 1.4 Hz), 3.89 (3H, s); ¹³C NMR (125 MHz, CDCl₃) δ_C 162.8, 162.5, 162.2, 149.7, 149.6, 142.0, 134.9, 131.9, 123.7, 121.3, 117.8, 116.3, 115.5, 109.0, 55.7; HRESI-MS *m/z* 235.0875 [M + H]⁺ (calcd for C₁₅H₁₁N₂O, 235.0871).

8-Hydroxyeupolauridine (1)

A solution of **10** (6 mg, 0.026 mmol) in 1 mL of 48% HBr was refluxed for 24 h. The mixture was then cooled and evaporated in vacuo to give a residue which was purified by PTLC on silica gel (hexanes:EtOAc, 6:4). 8-Hydroxyeupolauridine **1** (2.5 mg, 43 %) was collected as a yellow solid, mp 278–280 °C. Its ¹H NMR and HRESI-MS spectra were identical to those of the isolated material; ¹³C NMR, see Table 1.

8-Methoxyeupolauridine 1-oxide (11) and 9-methoxyeupolauridine 1-oxide (2)

A solution of 8-methoxyeupolauridine (**10**, 10 mg, 0.045 mmol) and *meta*-chloroperoxybenzoic acid, (7.4 mg, 0.043 mmol) in 1 mL CH₂Cl₂ was stirred at room temperature for 24 h. After the solvent was removed, the residue was separated by C-18 HPLC (60% MeOH:H₂O) to afford 9-methoxyeupolauridine 1-oxide (**2**) (1.6 mg, 15%) (mp 198–200 °C) and 8-methoxyeupolauridine 1-oxide (**11**) (5.9 mg, 55%). The NMR and mass spectroscopic data for **2** were identical to those of the natural product; ¹³C NMR, see Table 1.

8-Methoxyeupolauridine 1-oxide (11)

yellow solid, mp 218–220 °C; ¹H NMR (600 MHz, CD₃OD): δ_H 8.65 (1H, d, *J* = 5.8 Hz), 8.21 (1H, d, *J* = 8.5 Hz), 8.16 (1H, d, *J* = 7.1 Hz), 7.72 (1H, d, *J* = 7.1 Hz), 7.65 (1H, d, *J* = 5.8 Hz), 7.61 (1H, d, *J* = 2.3 Hz), 7.07 (1H, dd, *J* = 8.4, 2.4 Hz), 3.96 (3H, s); ¹³C NMR (150 MHz, CD₃OD) of **11**: δ_C 164.6, 159.3, 149.8, 145.6, 144.5, 141.1, 130.7, 128.4, 126.3, 125.3, 123.1, 119.3, 116.5, 111.2, 56.5; HRESI-MS *m/z* 251.0807 [M + H]⁺ (calcd for C₁₅H₁₁N₂O₂, 251.0821).

Antiproliferative Bioassays

The A2780 ovarian cancer cell line assay was performed at Virginia Polytechnic Institute and State University as previously reported,²⁵ except that the samples were added in 1 μL

100% DMSO per well instead of 20 μ L of 1:1 DMSO:H₂O. The A2780 cell line is a drug-sensitive human ovarian cancer cell line.²⁶ Assays against the H460 NSCLC lung cancer cell line were carried out at Eisai, Inc., as previously described.¹

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This International Cooperative Biodiversity Group project was supported by the Fogarty International Center, the National Cancer Institute, the National Institute of Allergy and Infectious Diseases, the National Institute of Mental Health, the National Institute on Drug Abuse, the National Heart Lung and Blood Institute, the National Center for Complementary and Alternative Medicine, the Office of Dietary Supplements, the National Institute of General Medical Sciences, the Biological Sciences Directorate of the National Science Foundation, and the Office of Biological and Environmental Research of the U.S. Department of Energy under Cooperative Agreement U01 TW00313 with the International Cooperative Biodiversity Groups. This project was also supported by the National Research Initiative of the Cooperative State Research, Education and Extension Service, USDA, Grant #2008-35621-04732. These supports are gratefully acknowledged. Work at Virginia Polytechnic Institute and State University was supported by the National Science Foundation under Grant CHE-0619382 for the purchase of the Bruker Avance 600 NMR spectrometer and Grant CHE-0722638 for the purchase of the Agilent 6220 mass spectrometer. We thank Mr. B. Bebout for obtaining the mass spectra, and Professor J. K. Zjawiony, University of Mississippi, for consulting with us on the structure of his synthetic compound **12**. Fieldwork essential for this project was conducted under a collaborative agreement between the Missouri Botanical Garden and the Parc Botanique et Zoologique de Tsimbazaza and a multilateral agreement between the ICBG partners, including the Centre National d'Application des Recherches Pharmaceutiques. We gratefully acknowledge courtesies extended by the Government of Madagascar (Ministère des Eaux et Forêts). We thank S. Randrianasolo, R. Rakotondrajaona, R. L. Andriamiarisoa, V. Benjara, and M. Velonjara for assistance with the plant collection.

References and Notes

1. Biodiversity Conservation and Drug Discovery in Madagascar, Part 47. For Part 46, see Pan E, Harinantenaina L, Brodie P, Callmender M, Rakotonandrasana S, Rakotobe E, Rasamison VE, TenDyke K, Shen Y, Suh EM, Kingston DGI. *Bioorg. Med. Chem.* 2011; 19:422–428. [PubMed: 21159516]
2. McLaughlin JL. *J. Nat. Prod.* 2008; 71:1311–1321. [PubMed: 18598079]
3. Nakanishi Y, Chang FR, Liaw CC, Wu YC, Bastow KF, Lee KH. *J. Med. Chem.* 2003; 46:3185–3188. [PubMed: 12852747]
4. Zhang HJ, Ma CY, Van Hung N, Cuong NM, Tan GT, Santarsiero BD, Mesecar AD, Soejarto DD, Pezzuto JM, Fong HHS. *J. Med. Chem.* 2006; 49:693–708. [PubMed: 16420055]
5. Wang S, Zhang YJ, Chen RY, Yu DQ. *J. Nat. Prod.* 2002; 65:835–841. [PubMed: 12088424]
6. Li C, Lee D, Graf TN, Phifer SS, Nakanishi Y, Riswan S, Setyowati FM, Saribi AM, Soejarto DD, Farnsworth NR, Falkinham JO, Kroll DJ, Kinghorn AD, Wani MC, Oberlies NH. *J. Nat. Prod.* 2009; 72:1949–1953. [PubMed: 19874044]
7. Li C, Lee D, Graf TN, Phifer SS, Nakanishi Y, Burgess JP, Riswan S, Setyowati FM, Saribi AM, Soejarto DD, Farnsworth NR, Falkinham JO, Kroll DJ, Kinghorn AD, Wani MC, Oberlies NH. *Org. Lett.* 2005; 7:5709–5712. [PubMed: 16321028]
8. Chang FR, Hwang TL, Yang YL, Li CE, Wu CC, Issa HH, Hsieh WB, Wu YC. *Planta Med.* 2006; 72:1344–1347. [PubMed: 17022008]
9. Khamis S, Bibby MC, Brown JE, Cooper PA, Scowen I, Wright CW. *Phytother. Res.* 2004; 18:507–510. [PubMed: 15305306]
10. Lekphrom R, Kanokmedhakul S, Kanokmedhakul K. *J. Ethnopharmacol.* 2009; 125:47–50. [PubMed: 19573585]
11. Waterman PG, Muhammad I. *Phytochemistry.* 1985; 24:523–527.
12. Rao JUM, Giri GS, Hanumaiah T, Rao KVJ. *J. Nat. Prod.* 1986; 49:346–347.
13. Peterson JR, Zjawiony JK, Liu S, Hufford CD, Clark AM, Rogers RD. *J. Med. Chem.* 1992; 35:4069–4077. [PubMed: 1433213]

14. Orabi KY, Li E, Clark AM, Hufford CD. *J. Nat. Prod.* 1999; 62:988–992. [PubMed: 10425122]
15. Leboeuf M, Cave A. *Lloydia*. 1977; 39:459–460. [PubMed: 1026846]
16. Bowden B, Picker K, Ritchie E, Taylor W. *Aust. J. Chem.* 1975; 28:2681–2701.
17. Tong TH, Wong HNC. *Synth. Commun.* 1992; 22:1773–1782.
18. Bracher F. *Arch. Pharm.* 1989; 322:293–294.
19. Zjawiony JK, Srivastava AR, Hufford CD, Clark AM. *Heterocycles*. 1994; 39:779–800.
20. Jiang C, Xu M, Wang S, Wang H, Yao Z-J. *J. Org. Chem.* 2010; 75:4323–4325. [PubMed: 20491491]
21. Zjawiony JK. Personal Communication. 2011 January 13.
22. Taylor WC. *Aust. J. Chem.* 1984; 37:1095–1104.
23. Hufford CD, Liu S, Clark AM, Oguntimein BO. *J. Nat. Prod.* 1987; 50:961–964. [PubMed: 3325614]
24. Muhammad I, Dunbar DC, Takamatsu S, Walker LA, Clark AM. *J. Nat. Prod.* 2001; 64:559–562. [PubMed: 11374943]
25. Cao S, Brodie PJ, Miller JS, Randrianaivo R, Ratovoson F, Birkinshaw C, Andriantsiferana R, Rasamison VE, Kingston DGI. *J. Nat. Prod.* 2007; 70:679–681. [PubMed: 17323994]
26. Louie KG, Behrens BC, Kinsella TJ, Hamilton TC, Grotzinger KR, McKoy WM, Winker MA, Ozols RF. *Cancer Res.* 1985; 45:2110–2115. [PubMed: 3986765]

Figure 1.
Favored resonance structures of **2** and **11**.

Scheme 1.

Synthesis of **1**, **2**, and **11**.

a) NaH, 1,4-dioxane, 30 min; b) H₂NOH.HCl, AcOH, 100–110 °C, 90 min, 32%; c) 40% NaOH/H₂O, reflux, 15h, 66%; d) SOCl₂, reflux, 24 h; e) AlCl₃, chlorobenzene, reflux, 15 h, 25%; f) (i) Me₂NCH(OEt)₂, DMF, 120 °C, 2 h; (ii) NH₄OAc, 140 °C, 1 h, 74%; g) 48% HBr, reflux, 24h, 43%; h) mCPBA, DCM, rt, 24 h, 70%.

Table 1
¹H and ¹³C NMR Spectra of Compounds **1–3** and ¹H NMR Spectra of Compounds **10** and **11**^a

position	1	2	3	10	11
	¹ H (J, Hz)	¹³ C ^b	¹ H (J, Hz) ^c	¹³ C	¹ H (J, Hz)
2	8.55 d (6.1)	150.3	8.58 d (6.0)	149.6	8.88 d (5.8)
3	7.61 d (6.1)	117.9	7.57 d (6.0)	117.8	7.71 d (5.8)
3a		137.0		130.4	
3b		122.7		125.0	
4	7.51 d (6.1)	119.7	7.79 d (7.1)	124.4	7.86 d (5.8)
5	8.64 d (6.1)	150.5	8.23 d (7.1)	145.8	9.11 d (5.8)
6a		163.1		144.0	
6b		143.0		136.3	
7	7.42 d (2.3)	112.3	7.92 d (2.4)	113.5	
7a				182.1	7.49 d (1.4)
8		164.2		139.2	
9	6.86 dd (8.2, 2.3)	118.2	7.09 dd (8.2, 2.4)	164.5	8.56 d (8.0)
10	7.78 d (8.2)	125.5	7.95 d (8.2)	117.1	7.77 t (8.0)
10a		130.9		125.4	7.26 d (8.0)
10b		163.6		130.7	
11				159.6	
11a				163.5	
11b				121.7	
11c				152.4	
OCH ₃			3.96 s	56.5	4.09
				4.05	3.90 s
				56.8	3.96 s

^aIn CD₃OD unless otherwise stated; δ (ppm); multiplicities; *J* values (Hz) in parentheses.

^bThe ¹³C NMR data on **1** and **2** were obtained on the synthetic samples.

^cIn CDCl₃; δ (ppm); multiplicities; *J* values (Hz) in parentheses.

Table 2Antiproliferative Activities of Compounds **1–6**, **10** and **11** against the A2780 and H460 Cancer Cell Lines

Cancer cell line	IC ₅₀ (μM)										
	1	2	3	4	5	6	10	11			
A2480	12.7	54.3	10.3	3.5	35.7	0.60	11.1	50.3			
H460	>10	>10	0.57	1.77	>100	0.58	>10	>100			